Cirrhosis and Its Complications¶
Chapter 355 | Part 10: Disorders of the Gastrointestinal System · Part 10 – Gastrointestinal Disorders · Chapter 355
Key Clinical Points¶
- Cirrhosis is defined histopathologically by architectural distortion with regenerative nodules and fibrosis.
- Alcohol-associated cirrhosis typically presents with an AST:ALT ratio >2:1 and AST <400 IU/mL.
- Primary Biliary Cholangitis (PBC) is characterized by AMA positivity in ~95% of cases and treated with UDCA (13–15 mg/kg/day).
- Primary Sclerosing Cholangitis (PSC) diagnosis requires cholangiographic imaging showing multifocal stricturing and beading.
- Portal hypertension is defined by a hepatic venous pressure gradient (HVPG) >5 mmHg; clinically significant portal hypertension (CSPH) is HVPG ≥ 10 mmHg.
- Variceal bleeding has a 20–30% mortality rate per episode; screening endoscopy is recommended for known cirrhotics.
- Hepatic encephalopathy is caused by portosystemic shunting and ammonia accumulation.
- Spontaneous bacterial peritonitis (SBP) is a major complication requiring empiric antibiotics in patients with ascites.
- Liver transplantation is the treatment of choice for decompensated cirrhosis due to PBC or PSC.
- Ascites pathophysiology involves both increased hydrostatic pressure (portal hypertension/splanchnic vasodilation) and decreased effective arterial blood volume (RAAS/sympathetic activation).
DEFINITION & OVERVIEW¶
• Definition: Cirrhosis is a condition that is defined histopathologically and has a variety of clinical manifestations and complications, some of which can be life-threatening. • Pathologic Features: ◦ Fibrosis to the point of architectural distortion with the formation of regenerative nodules. ◦ Result: Decrease in hepatocellular mass/function and alteration of blood flow. ◦ Mechanism: Activation of hepatic stellate cells → increased collagen and extracellular matrix production. ◦ Progression: Connective tissue in periportal and pericentral zones connects portal triads with central veins. ◦ Physical Change: Liver contracts and shrinks due to hepatocyte loss and collagen deposition. ◦ Timeline: Typically takes years to decades; requires repeated insults.
Classification by Etiology¶
• Categories (Table 355-1): ◦ Alcohol: Alcohol-associated fatty liver, Alcoholic hepatitis, Alcohol-associated cirrhosis. ◦ Chronic viral hepatitis: Hepatitis B, Hepatitis C. ◦ Autoimmune: Autoimmune hepatitis, Autoimmune cholangiopathy. ◦ Metabolic: Metabolic dysfunction–associated steatohepatitis (MASH). ◦ Biliary: Primary biliary cholangitis (PBC), Primary sclerosing cholangitis (PSC), Autoimmune cholangiopathy. ◦ Inherited: Hemochromatosis, Wilson’s disease, α Antitrypsin deficiency, Cystic fibrosis. ◦ Cardiac: Cardiac cirrhosis. ◦ Other: Cryptogenic cirrhosis.
EPIDEMIOLOGY¶
• General Statistics: ◦ Chronic liver disease is the 10th most common cause of death in US adults. ◦ Alcohol-associated cirrhosis accounts for ~48% of deaths due to cirrhosis. • Alcohol Use (US): ◦ >70% of adults drink alcohol annually. ◦ >14 million adults meet criteria for alcohol use disorder. • Hepatitis C (HCV): ◦ ~80% of exposed individuals develop chronic hepatitis C. ◦ ~20–30% of those with chronic infection develop cirrhosis over 20–30 years. ◦ ~170 million individuals worldwide have HCV. • Hepatitis B (HBV): ◦ ~5% of exposed individuals develop chronic HBV. ◦ ~20% of those with chronic HBV develop cirrhosis. ◦ ~300–400 million individuals have HBV worldwide; ~25% may develop cirrhosis. • Other Conditions: ◦ Hemochromatosis: 1 in 250 have genetic susceptibility, but <5% of these develop severe liver disease. ◦ Wilson’s disease: Affects 1 in 30,000 individuals. ◦ PBC: 100–200 per million; strong female predominance; median age ~50 at diagnosis.
ETIOLOGY & PATHOPHYISIOLOGY¶
• General Pathophysiology: ◦ Fibrosis → Architectural distortion → Regenerative nodules. ◦ Stellate cell activation → Collagen production → Liver shrinkage.
Alcohol-Associated Liver Disease Pathogenesis¶
• Metabolism: ◦ Absorption: Small intestine and stomach. ◦ Enzymes: Cytosolic ADH, MEOS (CYP2E1), Peroxisomal catalase. ◦ Pathway: Alcohol → Acetaldehyde (via ADH) → Acetate (via ALDH). ◦ MEOS Induction: Chronic use → CYP2E1 induction → Reactive oxygen species + more acetaldehyde. • Cellular Damage: ◦ Triglyceride accumulation → increased fatty acid uptake, decreased oxidation/secretion. ◦ Acetaldehyde effects: Forms adducts with proteins/nucleic acids; impairs enzyme activity and protein trafficking. ◦ Kupffer cell activation → release of profibrogenic cytokines → stellate cell activation.
Viral Hepatitis Pathogenesis¶
• HCV: ◦ Noncytopathic virus; damage is immune-mediated. ◦ Progression: Portal-based fibrosis → bridging fibrosis → nodularity → cirrhosis. ◦ Morphology: Small, shrunken liver; mixed micro- and macronodular cirrhosis; interface hepatitis. • HBV: ◦ Similar findings to HCV. ◦ Markers: HBsAg (ground-glass hepatocytes), HBc, and HBs antigens.
Biliary Cirrhosis Pathogenesis¶
• Mechanism: Result of chronic cholestasis. ◦ Features: Cholate stasis; copper deposition; xanthomatous transformation of hepatocytes; irregular, so-called biliary fibrosis. ◦ Distinction: Intrahepatic (no benefit from decompression) vs. Extrahepatic (may benefit from surgery/endoscopy).
Cardiac Cirrhosis Pathogenesis¶
• Mechanism: Right-sided congestive heart failure → increased venous pressure → dilated/engorged sinusoids. ◦ Result: Centrilobular hepatocyte necrosis → pericentral fibrosis → expansion to periphery.
Wilson’s Disease Pathogenesis¶
• Mechanism: Inherited disorder of copper homeostasis; failure to excrete copper → liver accumulation. ◦ Prevalence: 1 in 30,000; affects adolescents/young adults.
Alpha-1 Antitrypsin Deficiency Pathogenesis¶
• Mechanism: Inherited defect → abnormal folding of αAT protein → failure of secretion from liver. ◦ Risk: ZZ phenotype (only 10–20% develop liver disease). ◦ Pathology: PAS-positive, diastase-resistant globules.
CLINICAL FEATURES¶
• General Clinical Presentation: ◦ Severity reflects pathology. ◦ Distinction: Stable/Compensated vs. Decompensated (Ascites, Hepatic Encephalopathy, Variceal Bleeding). ◦ Portal Hypertension: Drives ascites and variceal bleeding. ◦ Loss of Function: Jaundice, coagulopathy, hypoalbuminemia.
Alcohol-Associated Liver Disease Clinical Features¶
• Diagnosis Criteria: ◦ History: >2 drinks/day (women) or >3 drinks/day (men) for >12 months. • Symptoms: Vague RUQ pain, fever, nausea, vomiting, diarrhea, anorexia, malaise. • Physical Exam: ◦ Liver/Spleen: Enlarged, firm, nodular. ◦ Skin: Scleral icterus, palmar erythema (Fig. 355-1), spider angioma (Fig. 355-2). ◦ Other: Parotid enlargement, digital clubbing, muscle wasting, edema, ascites. ◦ Male specific: Decreased body hair, gynecomastia, testicular atrophy. • Laboratory Findings: ◦ Anemia: Chronic blood loss, nutritional deficiency, or hypersplenism. ◦ Zieve’s Syndrome: Hemolytic anemia (spur cells/acanthocytes) in severe alcoholic hepatitis. ◦ Platelets: Reduced early due to portal hypertension/hypersplenism. ◦ Bilirubin: Normal or elevated in advanced disease. ◦ Coagulation: Prothrombin times prolonged; no response to Vitamin K. ◦ Sodium: Low if ascites present (free water ingestion). ◦ Enzymes: AST & ALT elevated; AST >1 ALT (usually 2:1 ratio); AST <400 IU/mL.
Primary Biliary Cholangitis (PBC) Clinical Features¶
• Presentation: Often asymptomatic until late. ◦ Fatigue: Significant, out of proportion to disease severity. ◦ Pruritus: ~50% at diagnosis; debilitating; worse in evening. ◦ Prognosis: Pruritus before jaundice indicates severe disease/poor prognosis. ◦ Unique features: Hyperpigmentation (trunk/arms), xanthelasma, xanthomata (altered cholesterol metabolism). ◦ Bone: Osteopenia or osteoporosis.
Primary Sclerosing Cholangitis (PSC) Clinical Features¶
• Symptoms: Fatigue, pruritus, steatorrhea, fat-soluble vitamin deficiencies. ◦ Physical: Signs of CHF; enlarged firm liver. ◦ Labs: ALP characteristically elevated; AST >1 ALT. ◦ Note: Variceal hemorrhage and encephalopathy are unlikely.
Other Types of Cirrhosis Clinical Features¶
• Cardiac: Signs of CHF, enlarged firm liver, elevated ALP. ◦ Wilson’s: Low ceruloplasmin, high 24-h urine copper, Kayser-Fleischer rings. ◦ Hemochromatosis: High transferrin saturation, high ferritin, HFE mutation. ◦ Cystic Fibrosis: Biliary-type cirrhosis; may benefit from UDCA.
DIFFERENTIAL DIAGNOSIS¶
• General Approach: ◦ Alcohol use → consider alcohol-associated liver disease. ◦ Rule out/identify other causes (viral, metabolic, autoimmune). ◦ Role of Biopsy: Helpful to confirm diagnosis but not performed unless alternative suspected. • Prognosis Factors: ◦ Continued drinking with complications → <50% 5-year survival. ◦ Abstinence → significantly improved prognosis.
Distinguishing Features by Etiology¶
• Alcohol-associated: AST:ALT >2:1; AST <400; history of >2/3 drinks for >12 months. ◦ Viral Hepatitis: Positive serologies (HBsAg, HCV RNA); ground-glass hepatocytes (HBV); portal-based fibrosis. ◦ Autoimmune Hepatitis: Positive ANA or ASMA; elevated IgG; interface hepatitis. ◦ MASH: Steatosis on biopsy. ◦ PBC: AMA positive (~95%); elevated IgM; cholestatic enzymes. ◦ PSC: pANCA positive (~65%); IBD association (60-80%); cholangiographic beading. ◦ Cardiac: Signs of heart failure, enlarged liver, elevated ALP, no variceal hemorrhage risk. ◦ Wilson's: Low ceruloplasmin, high urine copper, Kayser-Fleischer rings.
DIAGNOSTIC APPROACH¶
- Initial Assessment: History and Physical Examination (Alcohol use, symptoms, signs).
- Laboratory Evaluation: LFTs, Viral Serologies (HBsAg, HBeAg, anti-HBe, HCV RNA/Genotype), Iron Studies (Transferrin saturation, Ferritin), Autoantibodies.
- Specific Diagnostic Pathways: • PBC: If cholestatic enzymes abnormal → AMA test. ◦ If AMA negative (5–10%) → other antibodies (sp100, gp210) → Liver biopsy. • PSC: If AMA negative with cholestatic enzymes → Cholangiography (MRCP preferred; ERCP if MRCP is suboptimal or bilirubin rises). ◦ Criteria: Multifocal stricturing and beading of intra- and extrahepatic bile ducts. • Hemochromatosis: Serum iron studies (high transferrin saturation, high ferritin) + HFE mutation analysis. • Alpha-1 Antitrypsin: Determine αAT levels and phenotype. • Wilson's Disease: Ceruloplasmin (low), 24-h urine copper (high), Kayser-Fleichter rings, biopsy.
MANAGEMENT & TREATMENT¶
- Variceal Hemorrhage Management (Flowchart 1): • Step 1: Recurrent acute bleeding → Endoscopic therapy + Pharmacologic therapy. • Step 2: Control of bleeding achieved. • Step 3: Assess Child-Pugh score. • Step 4: If Child's class A (Compensated) → Perform TIPS → Consider liver transplantation evaluation. • Step 5: If Child's class B or C (Decompensated) → Transplant evaluation → Endoscopic therapy or beta blockers → Consider TIPS → Liver transplantation.
- Ascites Management (Flowchart 2): • Step 1: Highly symptomatic ascites → Large-volume paracentesis (LVP) + albumin. • Step 2: Maintenance → Dietary sodium restriction + diuretics. • Step 3: If Ascites reaccumulation occurs → Decision based on clinical status: ◦ Option A: Consider TIPS. ◦ Option B: Continue LVP with albumin as needed. ◦ Option C: Consider liver transplantation (especially if azotemia develops during diuretic treatment).
- Pharmacologic Therapy: • PBC: Treatment with Ursodeoxycholic acid (UDCA) at 13–15 mg/kg/day.
- Surgical/Procedural Therapy: • TIPS: Used for variceal bleeding or refractory ascites. • Transplantation: Preferred for decompensated cirrhosis due to PBC or PSC.
COMPLICATIONS & PROGNOSIS¶
• Portal Hypertension (Table 3): ◦ Prehepatic: Portal vein thrombosis, Splenic vein thrombosis, Massive splenomegaly (Banti's syndrome). ◦ Hepatic: Presinusoidal (Schistosomiasis, Congenital hepatic fibrosis). ◦ Sinusoidal: Cirrhosis (many causes), Alcoholic hepatitis. ◦ Postsinusoidal: Hepatic sinusoidal obstruction (venoocclusive syndrome), Budd-Chiari syndrome, Inferior vena caval webs, Cardiac causes (Restrictive cardiomyopathy, Constrictive pericarditis, Severe congestive heart failure). • General Complications (Table 2): ◦ Portal hypertension related: Gastroesophageal varices, Portal hypertensive gastropathy, Splenomegaly/hypersplenism, Ascites, Spontaneous bacterial peritonitis (SBP), Acute kidney injury-hepatorenor syndrome (HRS), Chronic kidney disease-hepatorenor syndrome. ◦ Coagulopathy: Factor deficiency, Fibrinolysis, Thrombocytopenia. ◦ Bone disease: Osteopenia, Osteoporosis, Osteomalacia. ◦ Hematologic: Anemia, Hemolysis, Neutropenia. • Other Complications: ◦ Hepatic encephalopathy. ◦ Hepatopulmonary syndrome. ◦ Portopulmonary hypertension. ◦ Malnutrition.
Classification of Portal Hypertension¶
• Prehepatic: Portal vein thrombosis, Splenic vein thrombosis, Massive splenomegaly (Banti's syndrome). • Hepatic: Presinusoidal (Schistosomiasis, Congenital hepatic fibrosis). • Sinusoidal: Cirrhosis (many causes), Alcoholic hepatitis. • Postsinusoidal: Hepatic sinusoidal obstruction (venoocclusive syndrome), Budd-Chiari syndrome, Inferior vena caval webs, Cardiac causes (Restrictive cardiomyopathy, Constrictive pericarditis, Severe congestive heart failure).
KEY PEARLS & HIGH-YIELD POINTS¶
• Variceal Hemorrhage: Mortality 20–30% per episode; screening endoscopy for all known cirrhotics. • Ascites Pathophysiology: Dual mechanism: \uparrow Hydrostatic pressure (Portal HTN) + \downarrow Effective arterial volume (RAAS/Sympathetic activation). • Alcoholic Cirrhosis: AST:ALT >2:1; AST <400; Zieve's syndrome (hemolytic anemia). • PBC vs. PSC: PBC is AMA+ (~95%); PSC is pANCA+ and associated with IBD. • TIPS Decision: Used for variceal bleeding or refractory ascites; choice of timing depends on Child-Pugh class. • Symptom Alert: Pruritus before jaundice in PBC indicates severe disease/poor prognosis.
Reference Tables¶
TABLE 355-1 Causes of Cirrhosis Alcohol Chronic viral hepatitis¶
Harrison's 22e, p.2708
| Alcohol | Cardiac cirrhosis |
|---|---|
| Chronic viral hepatitis | Inherited metabolic liver disease |
| Hepatitis B | Hemochromatosis |
| Hepatitis C | Wilson’s disease |
| Autoimmune hepatitis | α Antitrypsin deficiency 1 |
| Metabolic dysfunction-associated steatohepatitis |
Cystic fibrosis |
| Biliary cirrhosis | Cryptogenic cirrhosis |
| Primary biliary cholangitis | |
| Primary sclerosing cholangitis | |
| Autoimmune cholangiopathy | |
| 355 | Cirrhosis and Its Complications Alex S. Befeler, Bruce R. Bacon |
TABLE 355-3 Classification of Portal Hypertension Prehepatic¶
Harrison's 22e, p.2713
| Portal hypertension | Coagulopathy |
|---|---|
| Gastroesophageal varices | Factor deficiency |
| Portal hypertensive gastropathy | Fibrinolysis |
| Splenomegaly, hypersplenism | Thrombocytopenia |
| Ascites | Bone disease |
| Spontaneous bacterial peritonitis | Osteopenia |
| Acute kidney injury-hepatorenal syndrome | Osteoporosis |
| Chronic kidney disease-hepatorenal syndrome | Osteomalacia |
| Hematologic abnormalities | |
| Hepatic encephalopathy | Anemia |
| Hepatopulmonary syndrome | Hemolysis |
| Portopulmonary hypertension | Thrombocytopenia |
| Malnutrition | Neutropenia |
TABLE 355-3 Classification of Portal Hypertension
- Prehepatic
- Portal vein thrombosis
- Splenic vein thrombosis
- Massive splenomegaly (Banti’s syndrome)
- Hepatic
- Presinusoidal
- Schistosomiasis
- Congenital hepatic fibrosis
- Sinusoidal
- Cirrhosis—many causes
- Alcoholic hepatitis
- Postsinusoidal
- Hepatic sinusoidal obstruction (venoocclusive syndrome)
- Posthepatic
- Budd-Chiari syndrome
- Inferior vena caval webs
- Cardiac causes
- Restrictive cardiomyopathy
- Constrictive pericarditis
- Severe congestive heart failure